That the Parliament welcomes that the Glasgow-based company, Fraunhofer UK Research Limited, has been awarded almost £1 million of UK Government funding to develop breakthrough technology, which will look at how biomarkers found in blood can help with the early detection of dementia; recognises that Fraunhofer UK Research Limited, an organisation created in Glasgow, with its headquarters in the city, will seek to develop low-cost, autonomous and low-consumable bio-marker measurement instrumentation; notes that the Fraunhofer programme is one of 10 projects at the cutting edge of dementia research being awarded a share of £6 million of UK Government funding through Innovate UK’s Small Business Research Initiative (SBRI) dementia biomarker tools competition; understands that this investment forms part of the national Dame Barbara Windsor Dementia Mission to beat dementia, which was launched in August 2022 by the UK Government in honour of Dame Barbara and the millions of people and their loved ones that are affected by dementia; notes that the core purpose of the mission is to develop innovative research tools and boost the number and speed of clinical trials in dementia and neurodegeneration; acknowledges that the mission forms part of the UK Government’s commitment to double funding for dementia research to £160 million a year by 2024-25, and celebrates the UK Government's investment in what it sees as vital, game-changing work to tackle this devastating illness.